IDEXX Laboratories, Inc. (IDXX) Shares Bought by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1,000.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,100 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in IDEXX Laboratories were worth $172,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of IDXX. Koch Industries Inc. lifted its holdings in IDEXX Laboratories by 44,533.1% in the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in IDEXX Laboratories by 486.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock valued at $182,711,000 after acquiring an additional 938,888 shares during the last quarter. Atlantic Trust Group LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at about $65,381,000. Arrowstreet Capital Limited Partnership lifted its holdings in IDEXX Laboratories by 42.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in IDEXX Laboratories by 38.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after acquiring an additional 376,300 shares during the last quarter. 86.66% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on IDXX shares. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. BidaskClub downgraded shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, December 16th. Piper Jaffray Companies started coverage on shares of IDEXX Laboratories in a report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price target for the company. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Finally, Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $177.43.

In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total value of $8,171,280.00. Following the transaction, the chairman now owns 1,064,573 shares in the company, valued at approximately $161,091,186.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan W. Ayers sold 2,160 shares of the company’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $167.03, for a total value of $360,784.80. Following the completion of the transaction, the chief executive officer now owns 1,077,112 shares in the company, valued at approximately $179,910,017.36. The disclosure for this sale can be found here. Insiders have sold 130,160 shares of company stock valued at $20,019,685 over the last ninety days. Insiders own 2.77% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at $180.63 on Monday. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. IDEXX Laboratories, Inc. has a 52 week low of $116.54 and a 52 week high of $180.88. The company has a market cap of $15,754.37, a PE ratio of 58.46, a price-to-earnings-growth ratio of 2.43 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The company had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same period in the prior year, the firm earned $0.62 earnings per share. The business’s quarterly revenue was up 9.7% on a year-over-year basis. equities research analysts predict that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Shares Bought by Benjamin F. Edwards & Company Inc.” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://sportsperspectives.com/2018/01/22/idexx-laboratories-inc-idxx-shares-bought-by-benjamin-f-edwards-company-inc.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply